NEW HOPE, Pa.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB:PRTX) today announced that data from its Phase I clinical trial of PRTX-100 was presented at the American College of Clinical Pharmacology meeting in Boston, MA on September 17, 2006. The abstract was entitled: Phase I study of the safety and pharmacokinetics of staphylococcal protein A in healthy adults. PRTX-100 is in development for autoimmune disorders including rheumatoid arthritis and idiopathic thrombocytopenic purpura (ITP), a disorder in which the blood does not clot.
